Cipla is currently trading at Rs. 917.10, up by 1.50 points or 0.16% from its previous closing of Rs. 15.60 on the BSE.
The scrip opened at Rs. 915.60 and has touched a high and low of Rs. 918.10 and Rs. 901.95 respectively. So far 3438 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 1083.15 on 15-Mar-2022 and a 52 week low of Rs. 850.00 on 17-Dec-2021.
Last one week high and low of the scrip stood at Rs. 984.05 and Rs. 901.95 respectively. The current market cap of the company is Rs. 73880.42 crore.
The promoters holding in the company stood at 33.63%, while Institutions and Non-Institutions held 48.64% and 17.73% respectively.
Cipla has signed definitive agreements for acquisition of 21.05% stake (on a fully diluted basis) for an amount of Rs 25 crore (approximately) in Achira Labs engaged in development and commercialization of point of care (PoC) medical test kits in India.
This investment will facilitate a Cipla entity’s strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies.
A PoC that enables rapid identification of the bug causing an infection would be extremely helpful in choosing the appropriate antibiotic early in the treatment process.
Achira is developing POC immunoassays and molecular assays across the clinical areas of infectious diseases, anti-microbial resistance (AMR) and hormone analysis among others.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.